Member Info for miavoce

FDA meeting taking place before cohort 4 data is released so it must be imminent. Wonder if we'll get any feedback.

Hi Chelsea11, no reply from Scancell.

Interesting that the registration trial scope now includes neo-adjuvant as this will materially increase the cost of the trial...I wonder if a potential partner has pushed for this given the probability of success and the huge increase in market size.

Thanks Chelsea, I missed that.

'SCOPE results to date show progression-free survival (PFS) for iSCIB1+ in the target human leukocyte antigen (HLA) population at 11 months is 78%, compared with the historic 12-month PFS of 46% reported by doublet checkpoint therapy of ipilimumab and nivolumab.[1]'

I note that in the above sentence it says 'SCOPE results to date...' which IMO means as of today. So this is an update on the 24th July data and shows that the PFS is holding up really well as time progresses. In July the 11 month PFS was 81% whereas now it is 78%, and the 22 month PFS was previously 64% and is now reported as 69%.

I've dropped a note to Lindy asking about the publication of the AGM slides. Hopefully they will appear soon.

The SCOPE presentation isn't listed in any of the sessions on the 7th, it only features in session 206 on the 8th. Somewhat confusing given the references to the 7th mentioned by others. I guess we'll just have to wait and see whether / when the RNS pops up. GLA.

Have a look at the actual conference schedule Cleanerworld - it shows the presentation taking place at 14:30 on Saturday 8th.

JohnnyB1 look at session 206 on this page (Saturday) of the conference schedule:-

https://www.sitcancer.org/2025/schedule/sitc25-annualmeeting#tab2

Not sure if it has been posted already (apologies if so) but the Scancell poster will be presented at 14:30 EST on Saturday 8th November (15minute presentation), so if new data is released we will get the RNS on Monday morning.

Thanks for the reply TF. As you will have noticed my post was nothing to do with Scancell's science but instead was related to whether there is likely to be new data in the SITC presentation, and IMO the answer given by GROK was useful, well sourced, and worth sharing. Used appropriately AI can be very useful and I will certainly continue to use it - simply rejecting any use of AI to support research is IMO somewhat closed minded as to the potential benefits.

Regarding the AI bubble, I agree that the stock market valuations have gotten well ahead of themselves and that there will be a significant correction in due course (unless the revenues quickly start to justify the valuations). However, I do believe that AI has a very bright future and will become ever more prevalent in our daily lives as time progresses.

Moonparty I agree. I thought my question to GROK was neutral and the answer given was useful, hence sharing it.

I think most of us can tell the difference between AI garbage and decent AI output before sharing it on the BB. I thought the GROK output was very useful and continue to do so...or maybe I can't think for myself....

TF, what exactly did you find so distasteful about the information from GROK ? I found it helpful. When used well, I have found AI to be very useful both personally and professionally.

EE I thought GROK's reply was pretty good and sources were provided. Each to their own I guess.

The presentation will apparently be on the 8th rather than the 5th so the RNS, if there is to be one, will be on Monday 10th.

You not a fan of AI EE ?

Thanks Biblio, I have gone down that same route with GROK. Based on the answer new data is highly likely.

Question I asked:-

Scancell are presenting a late breaking abstract at the SITC event in the USA this week. The abstract relates to the interim results from the SCOPE trial. Scancell last gave a public update on the results in July this year. Is it possible that the abstract / presentation this week will include more recent data or does the deadline around the submission of late breaking abstracts for this event mean that it will not be possible to include data more recent than July ?

Answer given:-

Yes, it is possible—and in fact likely—that the late-breaking abstract and oral presentation for the SCOPE trial interim results at SITC 2025 (November 5–9) will include data more recent than the July 2025 public update.SITC's late-breaking abstracts (LBAs) are specifically reserved for high-impact data from interventional clinical trials that were not available by the regular abstract deadline (June 26, 2025, at 5 p.m. PT). (sitcancer.confex.com +1)

For SITC 2024, the LBA submission window was July 15 to September 12, and this year's LBAs are explicitly described as containing "late-breaking data from interventional clinical trials in humans." (oncodaily.com +1)

Scancell's SCOPE abstract (#1325) was selected as a clinical LBA for oral presentation on November 8, with the title emphasizing an "interim read-out." (prweb.com +1)

The July 2025 update reported positive interim data from the ongoing Phase 2 SCOPE trial, including efficacy, durability, immune responses, and safety for SCIB1/iSCIB1+ combined with checkpoint inhibitors in advanced unresectable melanoma. (globenewswire.com +1)

Since the trial is actively enrolling (e.g., Cohort 1 nearing 43 patients, with week-25 assessments for some cohorts expected in H1/H2 2025), additional patient follow-up, responses, or maturation of progression-free survival data would have accumulated by the LBA submission period (likely summer/early fall 2025, based on prior years). (calculuscapital.com +1)

Presenters often include the most mature data available in the final slides, even if the published abstract (released November 7 at 9 a.m. ET) reflects the submission cutoff. (prweb.com)

This aligns with SITC's emphasis on showcasing cutting-edge advancements, and Scancell's selection as an oral LBA alongside major institutions suggests updated insights beyond July.

Can somebody with knowledge of the process around late breaking abstracts kindly give a view on whether the presentation might include SCOPE data which is more recent than the July update or whether it is more likely to be a repeat of the July data. If the former i.e. new data, then I would expect an RNS with the new data on Thursday morning given that the presentation will take place after the market closes on Wednesday.

IHolyGrail